Fulton Bank N.A. Reduces Position in Astrazeneca Plc $AZN

Fulton Bank N.A. decreased its holdings in Astrazeneca Plc (NYSE:AZN) by 52.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,295 shares of the company’s stock after selling 8,127 shares during the period. Fulton Bank N.A.’s holdings in Astrazeneca were worth $1,439,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Triumph Capital Management acquired a new position in shares of Astrazeneca during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. purchased a new stake in shares of Astrazeneca in the fourth quarter valued at approximately $26,000. Bangor Savings Bank increased its holdings in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca in the fourth quarter valued at approximately $30,000. Finally, YANKCOM Partnership purchased a new position in Astrazeneca during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AZN shares. Weiss Ratings lowered Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Up 6.0%

AZN stock opened at $194.96 on Friday. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The firm has a market cap of $302.36 billion, a PE ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24. The firm’s 50 day moving average price is $183.91 and its 200-day moving average price is $187.76. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, equities research analysts anticipate that Astrazeneca Plc will post 10.28 EPS for the current year.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.